In January-June 2025, PJSC Lekhim-Kharkiv (Kharkiv) reduced its net profit by 6% compared to the same period in 2024, to UAH 28.072 million.
According to the company’s disclosure to the National Securities and Stock Market Commission, net sales revenue for the six months increased by 1.84% compared to the same period in 2024 and amounted to UAH 376.855 million.
As reported, PJSC Lekhim-Kharkiv produced 12.9 million packages of pharmaceutical products in 2024, with sales of its products reaching UAH 761.15 million in 2024, and net income from sales amounted to UAH 766.221 million.
In its report, the company noted that the main market for PJSC Lekhim-Kharkiv is Ukraine, with net income from sales on the domestic market amounting to UAH 564.612 million excluding VAT, or 81.2% of all products sold. At the same time, the company sold products worth almost UAH 50.844 million excluding VAT (7.3% of total sales) in distant foreign countries and UAH 80.207 million (11.5%) in neighboring countries.
In 2024, it supplied products to countries abroad, in particular Iraq and Mongolia, as well as to countries in the near abroad: Azerbaijan, Armenia, Moldova, Turkmenistan, and Uzbekistan.
As reported, in January-June 2024, Lekhim-Kharkiv increased its net profit by 6.9 times compared to the same period in 2023, to UAH 29.894 million. According to the company’s disclosure to the National Securities and Stock Market Commission, net sales revenue in January-June 2024 increased by 46.5% to UAH 369.934 million.
Lekhim JSC is part of the Lekhim pharmaceutical group (Kyiv) and owns 100% of Lekhim-Obukhiv LLC, 98.2% of Lekhim-Kharkiv PJSC, 81% of Technolog PJSC (Cherkasy region), 100% of Lekhim-Vilnius CJSC, and 100% of the foreign representative office of Lekhim in Uzbekistan.
